{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:05:54Z","timestamp":1790741154483,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by ARIAD Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3240-x","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:51Z","timestamp":1486598451000},"page":"507-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans"],"prefix":"10.1007","volume":"79","author":[{"given":"Yihua E.","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline N.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayana I.","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"3240_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/asheducation-2006.1.219","volume":"1","author":"MJ Mauro","year":"2006","unstructured":"Mauro MJ (2006) Defining and managing imatinib resistance. Hematol Am Soc Hematol Educ Program 1:219\u2013225","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"3240_CR2","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1080\/10428190701665988","volume":"48","author":"L Kujawski","year":"2007","unstructured":"Kujawski L, Talpaz M (2007) Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 48(12):2310\u20132322. doi: 10.1080\/10428190701665988","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"3240_CR3","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567\u20134576. doi: 10.1182\/blood-2011-05-355594","journal-title":"Blood"},{"issue":"11","key":"3240_CR4","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66(11):5790\u20135797. doi: 10.1158\/0008-5472.CAN-05-4187","journal-title":"Cancer Res"},{"issue":"12","key":"3240_CR5","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94(12):1765\u20131769. doi: 10.1038\/sj.bjc.6603170","journal-title":"Br J Cancer"},{"issue":"12","key":"3240_CR6","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"WS Huang","year":"2010","unstructured":"Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53(12):4701\u20134719. doi: 10.1021\/jm100395q","journal-title":"J Med Chem"},{"issue":"5","key":"3240_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412. doi: 10.1016\/j.ccr.2009.09.028","journal-title":"Cancer Cell"},{"issue":"1","key":"3240_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1\u201311. doi: 10.1111\/j.1747-0285.2010.01054.x","journal-title":"Chem Biol Drug Des"},{"issue":"22","key":"3240_CR9","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O\u2019Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075\u20132088. doi: 10.1056\/NEJMoa1205127","journal-title":"N Engl J Med"},{"issue":"19","key":"3240_CR10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"PACE","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, for the PACE Investigators (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369 (19):1783\u20131796. doi: 10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"issue":"9","key":"3240_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jcph.109","volume":"53","author":"NI Narasimhan","year":"2013","unstructured":"Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D (2013) Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol 53(9):974\u2013981. doi: 10.1002\/jcph.109","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"3240_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/js970486q","volume":"87","author":"CE Hop","year":"1998","unstructured":"Hop CE, Wang Z, Chen Q, Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87(7):901\u2013903. doi: 10.1021\/js970486q","journal-title":"J Pharm Sci"},{"issue":"10","key":"3240_CR13","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1124\/dmd.105.004283","volume":"33","author":"HP Gschwind","year":"2005","unstructured":"Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33(10):1503\u20131512. doi: 10.1124\/dmd.105.004283","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"3240_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1124\/dmd.110.032326","volume":"38","author":"A Gong","year":"2010","unstructured":"Gong A, Chen X, Deng P, Zhong D (2010) Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos 38(8):1328\u20131340. doi: 10.1124\/dmd.110.032326","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"3240_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2217\/pgs.10.99","volume":"11","author":"J Feng","year":"2010","unstructured":"Feng J, Sun J, Wang MZ, Zhang Z, Kim ST, Zhu Y, Xu J (2010) Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual\u2019s drug responses. Pharmacogenomics 11(10):1403\u20131425. doi: 10.2217\/pgs.10.99","journal-title":"Pharmacogenomics"},{"key":"3240_CR16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1054-3589(08)61043-1","volume":"27","author":"JL Hoffman","year":"1994","unstructured":"Hoffman JL (1994) Bioactivation by S-adenosylation, S-methylation, or N-methylation. Adv Pharmacol 27:449\u2013477","journal-title":"Adv Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3240-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T08:57:40Z","timestamp":1568797060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3240"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3240-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}